HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of tumour cells through activation of TRAIL-R1 and TRAIL-R2 death signalling receptors. Here, we describe the characterisation and activity of HGS-ETR1, the first fully human, agonistic TRAIL-R1 mAb that is being developed as an antitumour therapeutic agent. HGS-ETR1 showed specific binding to TRAIL-R1 receptor. HGS-ETR1 reduced the viability of multiple types of tumour cells in vitro, and induced activation of caspase 8, Bid, caspase 9, caspase 3, and cleavage of PARP, indicating activation of TRAIL-R1 alone was sufficient to induce both extrinsic and intrinsic apoptotic pathways. Treatment of cell lines in vitro with HGS-ETR1 enhanced the cytotoxicity of chemotherapeutic agents (camptothecin, cisplatin, carboplatin, or 5-fluorouracil) even in tumour cell lines that were not sensitive to HGS-ETR1 alone. In vivo administration of HGS-ETR1 resulted in rapid tumour regression or repression of tumour growth in pre-established colon, non-small-cell lung, and renal tumours in xenograft models. Combination of HGS-ETR1 with chemotherapeutic agents (topotecan, 5-fluorouracil, and irinotecan) in three independent colon cancer xenograft models resulted in an enhanced antitumour efficacy compared to either agent alone. Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1). Clearance was 3.6-5.7 ml(-1) day(-1) kg(-1). These data suggest that HGS-ETR1 is a specific and potent antitumour agent with favourable pharmacokinetic characteristics and the potential to provide therapeutic benefit for a broad range of human malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145,146,147].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Self-citationApo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 794
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Cited by
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
“It induces cell death in multiple tumor cell lines in vitro and in vivo, which can be enhanced by combination with chemotherapeutic agents like camptothecin, cisplatin, carboplatin, or 5-fluorouracil.(126) Mapatumumab demonstrated safety and tolerability in cancer patients with advanced solid tumors or non-Hodgkin’s l…”
BackgroundMethodInfluentialApoptosis: mechanisms and relevance in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1065-x · Cited by 344
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
“(HGS-ETR2) IgG1-λ TRAIL-R2 (DR5) Naïve scFv (79, 253) CAT Oncology”
BackgroundWilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
“Various agonistic human DR4 and DR5 antibodies display maximal proapoptotic signaling upon artificial Fc crosslinking (Ichikawa et al., 2001; Li et al., 2008; Natoni et al., 2007; Pukac et al., 2005; Yada et al., 2008; Zhang et al., 2007a).”
BackgroundPhase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247
Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Gimenez-Bonafe, P., Tortosa, A., & Perez-Tomas, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166600 · Cited by 196
The promise of TRAIL—potential and risks of a novel anticancer therapy
Koschny, R., Walczak, H., & Ganten, T. M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0194-1 · Cited by 195
“Showing promising results in preclinical studies [77], agonistic humanized mouse anti-TRAIL-R1 and anti-TRAILR2 mAb are currently used in clinical trials.”
BackgroundHotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Targeting death-inducing receptors in cancer therapy
Takeda, K., Stagg, J., Yagita, H., Okumura, K., & Smyth, M. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210374 · Cited by 186
“…it has been reported that agonistic anti-human DR4 or DR5 mAbs exhibited potent tumoricidal activities against human tumor xenografts in nude or SCID mice without apparent toxicity (Griffith et al., 1999; Chuntharapai et al., 2001; Ichikawa et al., 2001; Motoki et al., 2005; Pukac et al., 2005).”
BackgroundInfluentialTrarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
“Pre-clinical studies have shown that TRAIL and agonistic antibodies directed to TRAIL receptors can induce apoptosis in cancer cell lines and inhibit tumour growth in xenograft models (Pukac et al, 2005; Ashkenazi, 2008; Humphreys and Halpern, 2008; Johnstone et al, 2008).”
BackgroundKruyt, F. A. E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.003 · Cited by 172
“In cell lines and mice models, these antibodies potently induced apoptosis [40] [41].”
Georgakis, G. V., Li, Y., Humphreys, R., Andreeff, M., O'Brien, S., Younes, M., Carbone, A., Albert, V., & Younes, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05656.x · Cited by 171
“…recombinant proteins The agonistic monoclonal antibodies against TRAIL-R1 (HGSETR1) and TRAIL-R2 (HGS-ETR2) are fully human antibodies of IgG1 isotype (Dobson et al, 2002; Salcedo et al, 2002; Johnson et al, 2003; Pukac et al, 2005), and were provided by Human Genome Sciences (Rockville, MD, USA).”
BackgroundSelf-citationTRAIL in cancer therapy: present and future challenges
Mérino, D., Lalaoui, N., Morizot, A., Solary, E., & Micheau, O. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.10.1299 · Cited by 168
“These antibodies have been shown to induce apoptosis in human cancer cell lines and primary cells in vitro [160] , as well as in a variety of human tumours grown in immunodeficient mice [161,162] .”
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
Targeted manipulation of apoptosis in cancer treatment
Call, J. A., Eckhardt, S. G., & Camidge, D. R. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70209-2 · Cited by 165
Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
Pennarun, B., Meijer, A., de Vries, E. G. E., Kleibeuker, J. H., Kruyt, F., & de Jong, S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.004 · Cited by 162
TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies
MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. S., & Cohen, G. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2801 · Cited by 163
“Due to the selective toxicity of TRAIL to tumor cells (4), clinical trials have been initiated with HGS-ETR1 and HGS-ETR2 (Human Genome Sciences, Rockville, MD), selective agonistic antibodies for TRAIL-R1 and TRAIL-R2, respectively (5), and with Apo2L/TRAIL (Genentech, South San Francisco, CA).”
BackgroundCancer therapeutics: Targeting the apoptotic pathway
Khan, K. H., Blanco-Codesido, M., & Molife, L. R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.012 · Cited by 180
“As a single agent, mapatumumab was able o enhance the anti-tumor activity of cytotoxic agents in sevral cell lines, including those resistant to chemotherapy [48].”
BackgroundTargeting apoptosis as an approach for gastrointestinal cancer therapy
Qiao, L., & Yu, W. B. C. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.02.002 · Cited by 154
Deregulation of apoptosis in acute myeloid leukemia
Testa, U., & Riccioni, R. (2007) · Haematologica · doi:10.3324/haematol.10279 · Cited by 171
“Finally, EGS-ETR1 potentiated the anti-tumor efficacy of several chemotherapeutic drugs.(47) These observations clearly indicated that HGS-ETR1 has significant potential as a cancer therapeutic agent.”
BackgroundAdams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
Frew, A. J., Lindemann, R. K., Martin, B. P., Clarke, C. J. P., Sharkey, J., Anthony, D. A., Banks, K.-M., Haynes, N. M., Gangatirkar, P., Stanley, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801868105 · Cited by 145
Shin, S., Choi, D.-K., Jung, K., Bae, J., Kim, J., Park, S.-W., Song, K.-H., & Kim, Y. (2017) · Nature Communications · doi:10.1038/ncomms15090 · Cited by 149
Fractional killing arises from cell‐to‐cell variability in overcoming a caspase activity threshold
Roux, J., Hafner, M., Bandara, S., Sims, J. J., Hudson, H., Chai, D., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145584 · Cited by 139
“When we imaged ICRP in cells exposed to mapatumumab, a therapeutic antibody that functions as a DR4 agonist (Pukac et al, 2005), we observed the same dynamics as in TRAIL-treated cells: dFR/dt rose monotonically in dying cells, whereas in surviving cells, it peaked at t = 2–4 h and then fell (Fig…”
Principles of antibody-mediated TNF receptor activation
Wajant, H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.109 · Cited by 161
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Younes, A., Vose, J. M., Zelenetz, A. D., Smith, M. R., Burris, H. A., Ansell, S. M., Klein, J., Halpern, W., Miceli, R. C., Kumm, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605987 · Cited by 132
“Mapatumumab, like the native ligand TRAIL, mediates apoptosis by binding to TRAIL-R1, leading to activation of the caspase cascade, cleavage of key intracellular signalling components and DNA and subsequent cell death (Pukac et al, 2005).”
BackgroundTowards novel paradigms for cancer therapy
Pavet, V., Portal, M. M., Moulin, J.-F., Herbrecht, R., & Gronemeyer, H. (2010) · Oncogene · doi:10.1038/onc.2010.460 · Cited by 143
“Moreover, TRAIL exerts a potent tumoricidal activity in cancer cells in vitro and in vivo, causing negligible effects on normal cells when exogenously administered, an important feature of this cascade regarding its therapeutic potential (Walczak et al., 1999; Mitsiades et al., 2001; Naka et al., 2002; Georgakis et al…”
BackgroundIs TRAIL the holy grail of cancer therapy?
Newsom-Davis, T. E., Prieske, S., & Walczak, H. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0321-2 · Cited by 151
“Furthermore anti-TRAIL-R1 (HGS-ETR1) suppressed the growth of lung, colon and renal tumour xenografts in nude mice [95], whilst LZ-TRAIL suppressed growth of human breast cancer xenografts in severe combined immunodeficiency (SCID) mice [2].”
BackgroundLloyd, C., Lowe, D., Edwards, B. M., Welsh, F., Dilks, T., Hardman, C. H., & Vaughan, T. J. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn058 · Cited by 142
“Large libraries of phagedisplayed antibody fragments have proved to be a rich source of fully human antibodies for potential clinical development (Edwards et al., 2003; Pukac et al., 2005; Thompson et al., 1999).”
BackgroundSelf-citationKaplan-Lefko, P. J., Graves, J. D., Zoog, S. J., Pan, Y., Wall, J., Branstetter, D. G., Moriguchi, J., Coxon, A., Huard, J. N., Xu, R., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11264 · Cited by 126
Antibody engineering and modification technologies
Filpula, D. R. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.03.004 · Cited by 153
Georgakis, G. V., Li, Y., Rassidakis, G. Z., Martínez-Valdez, H., Medeiros, L. J., & Younes, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1194 · Cited by 136
Marini, P., Denzinger, S., Schiller, D., Kauder, S., Welz, S., Humphreys, R. C., Daniel, P. T., Jendrossek, V., Budach, W., & Belka, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209516 · Cited by 123
“HGS-ETR1 and HGSETR2 are high-affinity, recombinant, fully human, IgG1l monoclonal antibodies agonistic and specific to cell death receptors TRAIL-R1 or TRAIL-R2, respectively (Salcedo et al., 2002; Alderson et al., 2003; Pukac et al., 2005).”
BackgroundSelf-citationGieffers, C., Kluge, M., Merz, C., Sykora, J., Thiemann, M., Schaal, R., Fischer, C., Branschädel, M., Abhari, B. A., Hohenberger, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0323 · Cited by 114
“Agonistic anti-DR4 and -DR5 antibodies exerted potent anti-tumor activity as a single agent or in combination with chemotherapy in human tumor xenograft models in mice, including those based on human renal, colorectal, non-small cell lung and pancreatic cancer cell lines (7, 10, 11).”
BackgroundMultivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
Pavet, V., Beyrath, J., Pardin, C., Morizot, A., Lechner, M., Briand, J., Wendland, M., Maison, W., Fournel, S., Micheau, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2889 · Cited by 121
Monoclonal Antibodies in the Treatment of Non-Hodgkin???s Lymphoma
Fanale, M. A., & Younes, A. (2007) · Drugs · doi:10.2165/00003495-200767030-00002 · Cited by 111
Mom, C. H., Verweij, J., Oldenhuis, C. N. A. M., Gietema, J. A., Fox, N. L., Miceli, R. C., Eskens, F. A. L. M., Loos, W. J., de Vries, E. G. E., & Sleijfer, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0996 · Cited by 106
Mahdavi, S. Z. B., Oroojalian, F., Eyvazi, S., Hejazi, M., Baradaran, B., Pouladi, N., Tohidkia, M. R., Mokhtarzadeh, A., & Muyldermans, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.113 · Cited by 104
Jani, T. S., DeVecchio, J., Mazumdar, T., Agyeman, A., & Houghton, J. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091645 · Cited by 108
Death receptor agonist therapies for cancer, which is the right TRAIL?
Holland, P. M. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.12.009 · Cited by 107
“Conatumumab, drozitumab, tigatuzumab, and lexatumumab are all monoclonal agonist antibodies selectively targeting DR5, whereas mapatumumab is a fully human agonist antibody against DR4 [42–47].”
BackgroundFlusberg, D. A., Roux, J., Spencer, S. L., & Sorger, P. K. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-10-0737 · Cited by 96
“We conclude that TRAIL and Fas induce a resistant state in surviving cells and that this state can be sustained by further TRAIL treatments even in the absence of cell death.”
BackgroundTNF‐related apoptosis‐inducing ligand as a therapeutic agent in autoimmunity and cancer
Cretney, E., Shanker, A., Yagita∥, H., Smyth, M. J., & Sayers, T. J. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01413.x · Cited by 109
Park, K.-J., Lee, S.-H., Kim, T.-I., Lee, H.-W., Lee, C.-H., Kim, E.-H., Jang, J.-Y., Choi, K. S., Kwon, M.-H., & Kim, Y.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4766 · Cited by 95
“sensitive cells, but not in TRAIL-resistant cells (12, 13).”
BackgroundTear proteomics in keratoconus.
Pannebaker, C., Chandler, H. L., & Nichols, J. J. (2010) · PubMed Central · Cited by 95
Yada, A., Yazawa, M., Ishida, S., Yoshida, H., Ichikawa, K., Kurakata, S., & Fujiwara, K. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn015 · Cited by 94
“Similar discordance was observed for other anti-DR antibodies and TRAIL [6, 18].”
ResultIshibashi, M., & Ohtsuki, T. (2008) · Medicinal Research Reviews · doi:10.1002/med.20123 · Cited by 92
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling
Thorburn, A. M. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31805fea64 · Cited by 99
An introduction to death receptors in apoptosis
Kumar, R., Herbert, P. E., & Warrens, A. Ν. (2005) · International Journal of Surgery · doi:10.1016/j.ijsu.2005.05.002 · Cited by 113
Liu, H., Su, D., Zhang, J., Ge, S., Li, Y., Wang, F., Gravel, M., Roulston, A., Qin, S., Xu, W. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09518-1 · Cited by 97
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
Lim, B., Greer, Y. E., Lipkowitz, S., & Takebe, N. (2019) · Cancers · doi:10.3390/cancers11081087 · Cited by 90
Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells
De Miguel, D., Basáñez, G., Sánchez, D., Malo, P. G., Marzo, I., Larrad, L., Naval, J., Pardo, J., Anel, A., & Martinez-Lostao, L. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300258c · Cited by 81
Chodorge, M., Züger, S., Stirnimann, C. U., Briand, C., Jermutus, L., Grütter, M. G., & Minter, R. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.208 · Cited by 87
Treatment of metastatic cervical cancer: Future directions involving targeted agents
Díaz-Padilla, I., Monk, B. J., MacKay, H. J., & Oaknin, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.07.006 · Cited by 82
“[86] Pukac L, Kanakaraj P, Humphreys R, et al.”
BackgroundTargeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
Cohen, S. J., Cohen, R. B., & Meropol, N. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.194 · Cited by 92
Bin, L., Thorburn, J., Thomas, L. R., Clark, P. E., Humphreys, R. C., & Thorburn, A. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704210200 · Cited by 86
Self-citationAntibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Dubuisson, A., & Micheau, O. (2017) · Antibodies · doi:10.3390/antib6040016 · Cited by 84
“Developed by the Human Genome Science (HGS) in 2005, this fully human DR4-agonistic demonstrated selective and high binding to DR4, as well as cytotoxicity efficiency [98].”
BackgroundPoeta, G. D., Bruno, A., Principe, M. I. D., Venditti, A., Maurillo, L., Buccisano, F., Stasi, R., Neri, B., Luciano, F., Siniscalchi, A., et al. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908784293640 · Cited by 77
“high affinity and specificity for TRAIL-R1 [82].”
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145–147].”
Aspirin Sensitizes Cancer Cells to TRAIL–Induced Apoptosis by Reducing Survivin Levels
Lü, M., Strohecker, A. M., Chen, F., Kwan, T., Bosman, J. D., Jordan, V. C., & Cryns, V. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4362 · Cited by 75
Schultze, K., Böck, B. C., Eckert, A., Oevermann, L., Ramacher, D., Wiestler, O. D., & Roth, W. (2006) · APOPTOSIS · doi:10.1007/s10495-006-8896-3 · Cited by 75
“Agonistic TRAIL receptor antibodies have already been used in clinical phase 1 studies and have proven to be well-tolerated [13].”
MethodApoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy
Arguello, O. A. D., & Haisma, H. J. (2021) · Cancers · doi:10.3390/cancers13071543 · Cited by 84
van Geelen, C. M. M., Westra, J. L., de Vries, E. G. E., Ek, W. B., Zwart, N., Hollema, H., Boezen, H. M., Mulder, N. H., Plukker, J. T. M., de Jong, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8809 · Cited by 78
Luster, T. A., Carrell, J. A., McCormick, K., Sun, D. W., & Humphreys, R. C. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0918 · Cited by 67
“The agonistic TRAIL-R1 and TRAIL-R2 human IgG1 mAbs, mapatumumab and lexatumumab, respectively, were generated and purified as described previously (13).”
BackgroundMethodInfluentialSelf-citationAffinity maturation of phage display antibody populations using ribosome display
Groves, M. A. T., Lane, S., Douthwaite, J. A., Lowne, D., Rees, D. G., Edwards, B. M., & Jackson, R. H. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.04.002 · Cited by 67
Self-citationBelyanskaya, L. L., Marti, T. M., Hopkins-Donaldson, S., Kurtz, S., Felley‐Bosco, E., & Stahel, R. A. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-66 · Cited by 76
“Apoptosis-inducing mechanisms by human agonistic TRAIL-R antibodies Mapatumumab and Lexatumumab are thought to be similar to TRAIL-mediated apoptosis [13].”
BackgroundMacher‐Goeppinger, S., Aulmann, S., Tagscherer, K. E., Wagener, N., Haferkamp, A., Penzel, R., Brauckhoff, A., Hohenfellner, M., Sykora, J., Walczak, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0284 · Cited by 72
Jin, H., Yang, R., Ross, J., Fong, S., Carano, R. A. D., Tótpál, K., Lawrence, D. A., Zheng, Z., Koeppen, H., Stern, H. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0670 · Cited by 69
Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
Surget, S., Chiron, D., Gomez-Bougie, P., Descamps, G., Ménoret, E., Bataille, R., Moreau, P., Le Gouill, S., Amiot, M., & Pellat-Deceunynck, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0487 · Cited by 64
“The involvement of decoy receptors in the response to mapatumumab or lexatumumab should be excluded because these mAbs do not bind to the decoy receptors (39).”
BackgroundMénoret, E., Gomez‐Bougie, P., Geffroy-Luseau, A., Daniels, S. M., Moreau, P., Gouill, S. L., Harousseau, J., Bataille, R., Amiot, M., & Pellat‐Deceunynck, C. (2006) · Blood · doi:10.1182/blood-2005-12-007971 · Cited by 64
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta-Mateos, C., Alcaraz-Serna, A., Somovilla-Crespo, B., & Muñoz-Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 63
“Unlike native TRAIL, mapatumumab has longer half-life and binds specifically to TRAIL-R1 and not to the other TRAIL receptors (177).”
BackgroundNatoni, A., MacFarlane, M., Inoue, S., Walewska, R. J., Majid, A., Knee, D. A., Stover, D. R., Dyer, M. J. S., & Cohen, G. M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06852.x · Cited by 78
“…we utilized its different forms, including soluble ligands selective for TRAIL-R1 or TRAIL-R2, as well as mapatumumab (HGS-ETR1) and lexatumumab (HGSETR2) (Human Genome Sciences, Rockville, MD, USA), selective agonistic antibodies for TRAIL-R1 and TRAIL-R2 respectively (Pukac et al, 2005).”
MethodMaddipatla, S., Hernandez‐Ilizaliturri, F. J., Knight, J., & Czuczman, M. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0680 · Cited by 70
Zeng, Y., Wu, X., Fiscella, M., Shimada, O., Humphreys, R. C., Albert, V. R., & Kakehi, Y. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.2.421 · Cited by 67
“TRM-1 and HGS-ETR2 are fully human monoclonal antibodies (IgG1) isolated using phage-display technology in collaboration with Cambridge Antibody Technology (CAT) (27).”
MethodSelf-citationActivation of the Proapoptotic Death Receptor DR5 by Oligomeric Peptide and Antibody Agonists
Li, B., Russell, S. J., Compaan, D. M., Tótpál, K., Marsters, S. A., Ashkenazi, A., Cochran, A. G., Hymowitz, S. G., & Sidhu, S. S. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.06.042 · Cited by 65
Trail Receptors: Targets for Cancer Therapy
Humphreys, R. C., & Halpern, W. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_7 · Cited by 66
Self-citationFox, N. L., Humphreys, R. C., Luster, T. A., Klein, J. L., & Gallant, G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903319656 · Cited by 63
Self-citationNawrocki, S. T., Carew, J. S., Douglas, L., Cleveland, J. L., Humphreys, R. C., & Houghton, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0812 · Cited by 62
“Human Genome Sciences has recently developed fully humanized agonistic monoclonal antibodies that specifically recognize and activate TRAIL-R1 (mapatumumab) and TRAIL-R2 (lexatumumab) and are both being evaluated in clinical trials (3, 5, 26).”
BackgroundSelf-citationLi, X., Ruan, G., Lü, W.-L., Hong, H., Liang, G., Zhang, Y.-T., Yang, L., Long, C., Ma, X., Yuan, L., et al. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.007 · Cited by 60
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications
de Vries, E. G. E., Gietema, J. A., & de Jong, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0352 · Cited by 65
van Roosmalen, I. A. M., Quax, W. J., & Kruyt, F. A. E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.010 · Cited by 62
Emerging Biological Treatments for Uterine Cervical Carcinoma
Vici, P., Mariani, L., Pizzuti, L., Sergi, D., Lauro, L. D., Vizza, E., Tomao, F., Tomao, S., Mancini, E., Vincenzoni, C., et al. (2014) · Journal of Cancer · doi:10.7150/jca.7963 · Cited by 60
“Proteasome inhibition can enhance recombinant TRAIL-induced apoptosis in HPV positive cervical cells, and MoAbs against TRAIL have shown preclinical activity [113].”
BackgroundCiuleanu, T., Bazin, I. S., Lungulescu, D., Miron, L., Bondarenko, I., Deptała, A., Rodriguez‐Torres, M., Giantonio, B. J., Fox, N. L., Wissel, P. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw004 · Cited by 57
“The addition of mapatumumab to sorafenib did not improve TTP or other efficacy endpoints, nor did it alter the side-effect profile of sorafenib when administered in patients with advanced HCC. Based on these results, further development on the combination of mapatumumab and sorafenib in HCC is not planned. at O rta D…”
BackgroundInfluentialSelf-citationGao, S., Ding, D., & Gao, S. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s24094 · Cited by 59
Ciavarella, S., Milano, A., Dammacco, F., & Silvestris, F. (2010) · BioDrugs · doi:10.2165/11530830-000000000-00000 · Cited by 65
“A number of pre-clinical studies using mAbs to both DR5 and DR4, including lexatumumab, apomab, AMG655, CS-1008, LBY-135, and mapatumumab, are still under clinical testing, whereas preliminary phase II data have demonstrated promising safety and efficacy for some of these PARAs([107-109]) (figure 3).”
BackgroundInfluentialWajant, H. (2019) · Cancers · doi:10.3390/cancers11070954 · Cited by 60
“4H6 mIgG1 >1000 [72] 4G7 mIgG2a >1000 [72] DR4-A >100 [73] Mapatumumab (HGS-ETR1) hIgG1 Highly active w/o crosslinking [74]”
Phillips, D. C., Buchanan, F. G., Cheng, D., Solomon, L. R., Yu, X. H., Xue, J., Tahir, S. K., Smith, M. L., Zhang, H., Widomski, D. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2178 · Cited by 54
“Subsequently, a first generation of TRAIL-based therapeutics entered into clinical trials and mainly centered upon the recombinant form of human soluble TRAIL [sTRAIL; exemplified by Apo2L/AMG-951/ dulanermin, (10)] or agonistic antibodies that selectively target DR4 [mapatumumab, (11)] or DR5 [drozitumab, (12); conat…”
BackgroundSuzuki‐Karasaki, M., Ochiai, T., & Suzuki‐Karasaki, Y. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2215 · Cited by 54
Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S. J., Ponomarev, V., Diamond, P., Zannettino, A. C. W., Findlay, D. M., & Evdokiou, A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0745 · Cited by 60
Yoshida, T., Shiraishi, T., Horinaka, M., Wakada, M., & Sakai, T. (2007) · Oncology Reports · doi:10.3892/or.18.5.1239 · Cited by 57
“Recently, agonistic antibodies against DR4 and 5, which can substitute for the TRAIL function, have been developed (11,12).”
Targeting Death Receptors in Bladder, Prostate and Renal Cancer
O’Kane, H. F., Watson, C. J., Johnston, S. R., Peták, I., William, R., Watson, G. W., & Williamson, K. E. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00160-6 · Cited by 54
Ziauddin, M. F., Yeow, W.-S., Maxhimer, J. B., Baras, A., Chua, A., Reddy, R. M., Tsai, W. S., Cole, G. W., Schrump, D. S., & Nguyen, D. M. (2006) · Neoplasia · doi:10.1593/neo.05823 · Cited by 54
“[19] or recombinant human agonistic TRAIL-R1 monoclonal antibody [64] are commonly used to activate TRAIL receptor for the induction of apoptosis of cancer cells.”
MethodDolloff, N. G., Mayes, P. A., Hart, L. S., Dicker, D. T., Humphreys, R. C., & El‐Deiry, W. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001384 · Cited by 48
“S6 and in agreement with previous reports, mapatumumab induced a dose-dependent appearance of apoptotic markers (caspase-3 and PARP cleavage products) in TRAILsensitive SW480 cells (26).”
Self-citationMonoclonal antibodies: potential new therapeutic treatment against multiple myeloma
Allegra, A., Penna, G., Alonci, A., Russo, S., Greve, B., Innao, V., Minardi, V., & Musolino, C. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12107 · Cited by 52
Braun, F., Fecker, L. F., Schwarz, C., Walden, P., Assaf, C., Dürkop, H., Sterry, W., & Eberle, J. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700868 · Cited by 52
“Clinical trials have already been initiated in patients with advanced solid or hematological tumors (Pukac et al., 2005).”
Background
Metadata
- Authors
- Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X. T., Zhang, L., Zhong, L., von Kerczek, A., Shepard, L., Vaughan, T., Edwards, B., Dobson, C., Salcedo, T., & Albert, V
- Affiliations
- Human Genome Sciences (United States) (US)
- Recombinant Antibody Technology (United Kingdom) (GB)
- Corresponding author
- Pukac, L
- Venue
- British Journal of Cancer
- Published
- 2005-04
- Volume
- 92
- Issue
- 8
- Pages
- 1430-1441
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361994
- OpenAlex
- W1974144614
- Cited by
- 306
- References
- 56
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 11 · 2018: 3 · 2017: 8 · 2016: 8 · 2015: 12 · 2014: 7 · 2013: 13 · 2012: 16
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- TRAIL-R1, TRAIL receptor 1, agonistic monoclonal antibody, TRAIL, apoptosis, caspase activation, PARP cleavage, combination chemotherapy, colon cancer, non-small cell lung cancer, renal tumours, xenograft models, pharmacokinetics, cancer therapy
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Specificity, Antineoplastic Agents, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Half-Life, Humans, Male, Mice, Nude, Neoplasms, Experimental, Blotting, Western, Apoptosis, Receptors, Tumor Necrosis Factor, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.